These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 36325813)

  • 1. Visual outcome, ocular findings, and visual quality of life in patients with Fabry disease.
    Nilsson M; Kolagari HT; Epstein D; Samolov B; Olsson M; Naess K; Oscarson M; Teaer Fahnehjelm K
    Ophthalmic Genet; 2022 Dec; 43(6):841-849. PubMed ID: 36325813
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fabry disease and chemosis.
    Edwards JD; Bower KS; Brooks DB; Walter A
    Cornea; 2009 Feb; 28(2):224-7. PubMed ID: 19158572
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ophthalmological manifestations of Fabry disease: a survey of patients at the Royal Melbourne Fabry Disease Treatment Centre.
    Nguyen TT; Gin T; Nicholls K; Low M; Galanos J; Crawford A
    Clin Exp Ophthalmol; 2005 Apr; 33(2):164-8. PubMed ID: 15807825
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Computer assisted evaluation of retinal vessels tortuosity in Fabry disease.
    Sodi A; Guarducci M; Vauthier L; Ioannidis AS; Pitz S; Abbruzzese G; Sofi F; Mecocci A; Miele A; Menchini U
    Acta Ophthalmol; 2013 Mar; 91(2):e113-9. PubMed ID: 23164241
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ocular manifestations of Fabry's disease: data from the Fabry Outcome Survey.
    Sodi A; Ioannidis AS; Mehta A; Davey C; Beck M; Pitz S
    Br J Ophthalmol; 2007 Feb; 91(2):210-4. PubMed ID: 16973664
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ophthalmic experience over 10 years in an observational nationwide Danish cohort of Fabry patients with access to enzyme replacement.
    Fledelius HC; Sandfeld L; Rasmussen ÅK; Madsen CV; Feldt-Rasmussen U
    Acta Ophthalmol; 2015 May; 93(3):258-64. PubMed ID: 25487570
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Ophthalmic manifestations in Mexican patients with Fabry disease].
    Beltrán-Becerra KJ; Ríos-González BE; Gutiérrez-Amavizca BE; Silva-Noriega DA; Figuera LE
    Arch Soc Esp Oftalmol; 2012 Nov; 87(11):373-5. PubMed ID: 23058197
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ocular manifestations in Fabry disease: a survey of 32 hemizygous male patients.
    Orssaud C; Dufier J; Germain D
    Ophthalmic Genet; 2003 Sep; 24(3):129-39. PubMed ID: 12868031
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Paediatric Fabry disease: prognostic significance of ocular changes for disease severity.
    Kalkum G; Pitz S; Karabul N; Beck M; Pintos-Morell G; Parini R; Rohrbach M; Bizjajeva S; Ramaswami U
    BMC Ophthalmol; 2016 Nov; 16(1):202. PubMed ID: 27852300
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Corneal densitometry: a potential indicator for early diagnosis of Fabry disease.
    Li S; Siggel R; Guo Y; Loreck N; Rokohl AC; Kurschat C; Heindl LM
    Graefes Arch Clin Exp Ophthalmol; 2021 Apr; 259(4):941-948. PubMed ID: 33258999
    [TBL] [Abstract][Full Text] [Related]  

  • 11. COMPUTER ASSISTED RETINAL VESSEL TORTUOSITY EVALUATION IN NOVEL MUTATION FABRY DISEASE: Towards New Prognostic Markers.
    San Román I; Rodríguez ME; Caporossi O; Zoppetti C; Sodi A; Mecocci A; López D; Rodríguez B; Gimeno JR
    Retina; 2017 Mar; 37(3):592-603. PubMed ID: 28225726
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessment of corneal topographic, tomographic, densitometric, and biomechanical properties of Fabry patients with ocular manifestations.
    Cankurtaran V; Tekin K; Cakmak AI; Inanc M; Turgut FH
    Graefes Arch Clin Exp Ophthalmol; 2020 May; 258(5):1057-1064. PubMed ID: 31915973
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ocular signs correlate well with disease severity and genotype in Fabry disease.
    Pitz S; Kalkum G; Arash L; Karabul N; Sodi A; Larroque S; Beck M; Gal A
    PLoS One; 2015; 10(3):e0120814. PubMed ID: 25781336
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Conjunctival lymphangiectasia associated with classic Fabry disease.
    Sivley MD; Wallace EL; Warnock DG; Benjamin WJ
    Br J Ophthalmol; 2018 Jan; 102(1):54-58. PubMed ID: 28500230
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Autophagy-lysosome pathway alteration in ocular surface manifestations in Fabry disease patients.
    Marenco M; Segatto M; Sacchetti M; Mangiantini P; Giovannetti F; Plateroti R
    Orphanet J Rare Dis; 2022 Jul; 17(1):291. PubMed ID: 35870972
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Retinal hyperreflective foci in Fabry disease.
    Atiskova Y; Rassuli R; Koehn AF; Golsari A; Wagenfeld L; du Moulin M; Muschol N; Dulz S
    Orphanet J Rare Dis; 2019 Dec; 14(1):296. PubMed ID: 31878969
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Subclinical optic neuropathy in Fabry disease.
    Pitz S; Grube-Einwald K; Renieri G; Reinke J
    Ophthalmic Genet; 2009 Dec; 30(4):165-71. PubMed ID: 19852573
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rats deficient in α-galactosidase A develop ocular manifestations of Fabry disease.
    Miller JJ; Aoki K; Reid CA; Tiemeyer M; Dahms NM; Kassem IS
    Sci Rep; 2019 Jun; 9(1):9392. PubMed ID: 31253878
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Longitudinal study on ocular manifestations in a cohort of patients with Fabry disease.
    Michaud L
    PLoS One; 2019; 14(6):e0213329. PubMed ID: 31246960
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.